The United States health advisers supported a Johnson & Johnson coronavirus vaccine booster Friday, mentioning concern that American people who received the single-shot are not as protected as those who received two-shots brands. Johnson & Johnson told the Food & Drug Administration (FDA) that an additional shot adds significant protection as soon as two months after first vaccination – but that it might work better if individuals wait until six months later.
The advisory panel of the FDA voted unanimously that booster dose should be offered at least two months after individuals received their initial dose. However, Dr. Paul Office of Children’s Hospital of Philadelphia, the FDA adviser, said that it was always a two-shot vaccine. Moreover, the FDA is not bound by the endorsement as it makes a concluding decision – and adding to the complexity of the debate, new research also suggests that Johnson & Johnson recipients might have a stronger immune response if their booster shot is from a competing brand.
FDA panel endorses a booster shot for J&J’s COVID-19 vaccine
U.S. health advisors have unanimously endorsed Johnson & Johnson’s booster shot for COVID-19 for adults.
— Brody Levesque (@BrodyLevesque) October 15, 2021
Initial results from ongoing research of different ways to mix and match different doses showed that a booster shot of any type increased people’s levels of antibodies – at least for some weeks. FDA’s advisers did not vote on whether that should endorse but told the administration to allow flexibility with vaccine boosters. Dr. Ofer Levy of Boston Children’s Hospital said that in the real world, all these combinations are already occurring, so it is a matter of some urgency for the Food and Drug Agency to help sort out what is definitely a challenging and complex scenario.
All Three Vaccines Continue to Offer Strong Protection
The Biden government says that all three United States vaccines continue to offer robust and effective protection against severe illness, hospitalization, and death from coronavirus and that the priority is getting initial shots to the sixty-six million eligible but unvaccinated nationals who are most at risk. However, the country is moving toward a wider booster vaccine campaign with the spread of the more infectious delta variant and signs of weakening immunity against minor infections.
Pfizer boosters began offering boosters last month to seniors and youngsters at high risk from coronavirus because of poor health, living conditions, or jobs – at least six months after their first vaccination. The FDA advisory panel endorsed the same approach on Thursday for half-shot Moderna boosters. However. Johnson & Johnson vaccine constantly exposed lower effectiveness levels across several studies – and the FDA panel finally settled on an additional dose for any American eighteen or older at least two months after their initial vaccination.
The FDA will use the recommendations of its advisers to decide whether to approve booster shots for both Moderna and J&J. next, the U.S. Centers for Disease Control & Prevention (CDC) would rule on who should get ready to take them. The huge majority of the one hundred and eighty-eight million American nationals who received full vaccination against coronavirus received the Moderna or Pfizer options, while Johnson & Johnson recipients account for only around fifteen million. J&J COVID-19 vaccine made of different technology, and the company pitched its booster dose as a way to strengthen a strong vaccine that, according to them, retained its protective power over eight months.